Six female adult Macaca mulatta monkeys were made dependent upon morphine sulfate and wermanted with a chronic indwelling needle in the lateral ventricle of the brain for sterile intraventricular injections. Both B-endorphin and morphine, in a dose dependent manner given intraventricularly suppressed the signs of 14 hour acute morphine abstinence. On a molar basis, 8-endorphin was more active than morphine in suppressing the signs of morphine abstinence. When given intravenously in much larger doses, B-endorphin was ineffective in contrast to morphine which was effective in suppressing abstinence.
Introduction
The evidence that 8-endorphin is a narcotic agonist when given intraventricularly to rodents is very impressive. This untriakontapeptide, B-endorphin, of camel and human pituitary glands, isolated and synthesized by , is a potent narcotic analgesic. When compared to morphine in mice, B-endorphin is 18-33 times more potent when given intraventricularly (5) but 3-4 times more potent when given intravenously (6). As is typical of a narcotic agonist, tolerance to and physical dependence on B-endorphin and naloxone antagonism of its acute effects have been demonstrated in rodents (7, 8, 9) . When given intravenously to narcotic dependent humans, B-endorphin has been reported to suppress the acute abstinence syndrome (10,ll). In cats, B-endorphin given intraventricularly also produces narcotic-like manic behavior (12,13). However, intravenous injection of B-endorphin to humans does not produce a typical narcotic-like state (14). In fact, the evidence that intravenous B-endorphin has a central opioid action in primates is very poor. Additional studies of B-endorphin compared to morphine in morphine dependent monkeys seem imperative. We report here the effectiveness of B-endorphin in suppressing acute withdrawal in chronic morphine-dependent monkeys, but only when this peptide is given intraventricularly.
Materials and Methods
Six adult female monkeys, weighing from 3 to 5 kg were made dependent upon morphine with daily injections of 3.0 mg/kg of morphine sulfate subcutaneously every 6 hours at 7:00 a.m., 1:00 p.m., 7:00 p.m., and 1:00 a.m. for periods up to 2 years. They were fed a commercial monkey chow dusted with isoniazid for an estimated isoniazid dose of 10 mg/kg. All six animals were housed in one large gang cage. Each animal was prepared surgically under ketamine anesthesia with a special chronic indwelling stainless steel needle which contained a rubber septum covered with silastic for sterility. Evidence that the needle was in the lateral ventricle was obtained by withdrawal of ventricular fluid and via skull x-rays obtained after injection of 0.2 and 1.0 ml of the radiocontrast media metrizamide (250 mg of iodine/ml). The distribution of 0.2 ml of metrizimide given intraventricularly is illustrated in one monkey, M900 in Fig. 1 . At approximately l-4 week intervals the animals were subjected to 14 hour abstinence in which the 1:00 and '7:00 a.m. doses of morphine were omitted. Each experiment began at about 9:00 a.m. or 14 hours after the previous 7:00 p.m. dose of morphine. Abstinence signs were scored before drug injection and at various times thereafter. Morphine and synthetic human i3-endorphin (4) were dissolved in artificial cerebrospinal fluid (15). To maintain sterility, all solutions were passed through separate SLG SO25 OS Millex disposable millipore filters prior to injection. Each drug was given intraventricularly or intravenously in doses of 10, 32, 100, 320, 570 and sometimes 1000 ug in a random fashion over an experimental design which lasted one year. Not all six animals completed all of the doses scheduled for various reasons but all animals received most of the doses of all drugs. The drug dosages were compared with an equal volume of artificial cerebrospinal fluid. During the experimental period over 1 to 2 years, two of the animals died from acute cerebral ventriculitis due to faulty sterile procedures. Abstinence scores were obtained using an 8 point scale as previously described (16) (17) (18) (19) (20) . These signs are grouped in the following categories: general behavior in the home cage, facial, trunk and extremity characteristics, autonomic signs, and those signs elicited by a handling routine. The handling routine was by far the most sensitive means of measuring abstinence. When abstinence was not terminated with an injection of the scheduled substance, it was then routinely terminated with 10 mg/kg morphine subcutaneously and continuation of morphine injection every 6 hours beginning at 1:00 a.m. the night after the day's experiment.
Results and Discussion
The administration of artificial cerebrospinal fluid (0.2 ml), either intraventricularly or intravenously, had no effect on morphine abstinence !see Fig. 2 ). In contrast, 100 ug of either morphine or B-endorphin given intraventricularly was very effective in suppressing morphine abstinence. However, when given intravenously in a dose of 100 ug, neither morphine nor fi-endorphin had any significant effect, indicating that at this dose both substances have only a central nervous system site of action to suppress withdrawal.
The effects of increasing doses of 8-endorphin given intraventricularly on abstinence severity in two morphine dependent monkeys is shown in Fig. 3 . Effects of intraventricular B-endorphin on abstinence severity in two monkeys, M900 and M907. There was considerable variability in the effectiveness of both morphine and .6-endorphin in suppressing the severity of morphine abstinence as shown in the data from another three monkeys. This is illustrated in Fig. 4 .
The dose (pmol)-area of the response relations of B-endorphin and morphine, given intraventricularly, are shown in Fig. 5 for two morphine-dependent monkeys undergoing abstinence. Both substances suppress withdrawal signs but 8-endorphin is much more potent on a molar basis (about 35X) and has a greater central nervous system depressant component. A larger dose of morphine (1000 ug) given intraventricularly to one monkey caused grand ma1 seizures. In contrast, no gross seizures were observed with &endorphin.
As described above, doses of both Pendorphin and morphine which were effective in suppressing morphine withdrawal when given intraventricularly were ineffective when given intravenously. This indicates that morphine withdrawal and its suppression occurs in the brain and not at peripheral sites. Furthermore, in all six monkeys morphine in doses up to 10 mg/kg given either subcutaneously or intravenously was extremely effective in suppressing morphine withdrawal-In contrast, B-endorphin given intravenously in large doses of 1, 3.2 and 9 mg/kg was totally ineffective as shown in the data for monkey M893 in Fig. 6 .
